The liquid biopsy in lung cancer.
The liquid biopsy in lung cancer.
复制标题
DOI：
10.18632/genesandcancer.127
复制
发表时间：
2016-11
期刊：
影响因子：
--
通讯作者：
Shackelford RE
中科院分区：
文献类型：
--
作者：
Ansari J;Yun JW;Kompelli AR;Moufarrej YE;Alexander JS;Herrera GA;Shackelford RE
在上个世纪，肺癌的发病率显著增加，主要是由于吸烟，并且仍然是全世界癌症死亡的最常见原因。这通常是由于肺癌首先出现在晚期，并且在这些晚期阶段缺乏治愈性治疗选择。由于组织活检的局限性，延迟诊断、肿瘤取样不足和肺癌误诊也并不罕见。我们对肿瘤微环境和肿瘤的全身作用有了更好的理解，再加上最近液体活检的出现，可能会允许对循环肿瘤标志物，特别是循环肿瘤DNA进行分子诊断。目前正在研究多种液体活检分子方法，以确定其作为肿瘤组织活检替代物的功效。本综述将重点介绍新的液体活检技术，以及它们如何有助于肺癌的检测、诊断和治疗。
The incidence of lung cancer has significantly increased over the last century, largely due to smoking, and remains the most common cause of cancer deaths worldwide. This is often due to lung cancer first presenting at late stages and a lack of curative therapeutic options at these later stages. Delayed diagnoses, inadequate tumor sampling, and lung cancer misdiagnoses are also not uncommon due to the limitations of the tissue biopsy. Our better understanding of the tumor microenvironment and the systemic actions of tumors, combined with the recent advent of the liquid biopsy, may allow molecular diagnostics to be done on circulating tumor markers, particularly circulating tumor DNA. Multiple liquid biopsy molecular methods are presently being examined to determine their efficacy as surrogates to the tumor tissue biopsy. This review will focus on new liquid biopsy technologies and how they may assist in lung cancer detection, diagnosis, and treatment.